Biosenic
BIOS
Company Profile
Business description
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.
Contact
Rue Granbonpre 11
Batiment H (bte 24)
Mont-St-Guibert1435
BELT: +32 493097366
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Chart of the Week: Has gold reached bear market territory?
Investors are facing a shifting landscape.
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,849.10 | 23.40 | 0.27% |
| CAC 40 | 7,816.94 | 44.49 | 0.57% |
| DAX 40 | 22,680.04 | 117.16 | 0.52% |
| Dow JONES (US) | 46,341.51 | 1,125.37 | 2.49% |
| FTSE 100 | 10,176.45 | 48.49 | 0.48% |
| HKSE | 25,328.28 | 540.14 | 2.18% |
| NASDAQ | 21,590.63 | 795.99 | 3.83% |
| Nikkei 225 | 53,128.33 | 2,064.61 | 4.04% |
| NZX 50 Index | 12,869.18 | 42.93 | -0.33% |
| S&P 500 | 6,528.52 | 184.80 | 2.91% |
| S&P/ASX 200 | 8,635.60 | 16.90 | 0.20% |
| SSE Composite Index | 3,950.75 | 58.89 | 1.51% |